Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data. Journal Abstract

Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.

Publication Date: 2024 Aug

Full Text Sources

Atypon

Ovid Technologies, Inc.

Authors

William Wang; Nora D Volkow; Nathan A Berger; Pamela B Davis; David C Kaelber; Rong Xu

Abstract

OBJECTIVE

Reports of reduced desire to smoke in patients treated with semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA) medication for type 2 diabetes mellitus (T2DM) and obesity, have raised interest about its potential benefit for tobacco use disorders (TUDs).

Source

Annals of internal medicine

Pub Types(s)

Journal Article

Language

English

PubMed ID

39074369